CellVive NMN® Advance is formulated using CellVive NMN®, the first NMN ingredient permitted for use in listed medicines in Australia. Our formulation combines CellVive NMN® with PlexoZome® delivery technology, which encapsulates the NMN in liposomes for gastrointestinal absorption. Elevate CellVive NMN® has been developed in partnership with scientists and research institutions and is manufactured in Australia. As a listed medicine, Elevate CellVive NMN® is required to be manufactured under quality Good Manufacturing Practice (GMP).

CellVive NMN® Advance is a therapeutic good under the listed medicine category and has been entered into the Australian Register of Therapeutic Goods (ARTG) with AUST L 521452, and as such is permitted for free sale in Australia. Listed medicines are manufactured to quality standards under Good Manufacturing Practice (GMP).

PlexoZome® delivery technology utilises liposomes to encapsulate active ingredients. Liposomes are tiny spheres. Each sphere includes a fat-based outer layer that surrounds water-loving ingredients in the centre, such as NMN. The outer layer shields the active ingredient from the gastrointestinal environment, allowing the active ingredient to be absorbed intact through the gastrointestinal membrane.